Join Ayla Networks for Hands-on IoT Lab in London, Berlin, Amsterdam
Ayla Networks announced a series of Hands-on IoT Lab tour dates in Europe to provide participants an opportunity to experience for themselves how to build a prototype connected product, connect it to the cloud and modify and control it while it’s connected.
“Our Hands-on IoT Lab provides participants with an opportunity to go behind the scenes of the Internet of Things (IoT) with Ayla Networks and our pioneering IoT platform,” said Michael Setton, regional director, Greater European Markets for Ayla Networks.
What: The Ayla Hands-On IoT Lab is a two-hour session designed to provide participants with first-hand experience building an IoT-connected product. Using the Ayla developers’ kit, which includes a board with an Ayla-enabled Broadcom radio chip built on a USI module, participants in the Hands-on IoT Lab can experience the complete life cycle in creating a connected product: from platform evaluation to proof of concept to prototyping to final productization.
Time and Location Details for Each Ayla Hands-on IoT Lab
London Hands-on IoT Lab
When: Tuesday, October 20, 6:30 pm – 8:30 pm (18:30 pm to 20:30 pm)
Where: AWS Loft Space, 6th Floor, WeWork, Moorgate Place, 1 Fore St, London, EC2Y 5EJ
Berlin Hands-on IoT Lab
When: Tuesday, November 3, 9:00 am – 11:00 am
Wednesday, November 4, 9:00 am – 11:00 am
Where: AWS Loft Space, Krausenstrasse 38, 10117 Berlin-Mitte, Berlin
Amsterdam Hands-on IoT Lab at the Parks CONNECTIONS Show
When: Wednesday, November 11, 6:00 pm – 8:00 pm (18:00 pm to 20:00 pm)
Where: NH Grand Hotel Krasnapolsky, Dam 9, 1012 JS Amsterdam, Netherlands
Register: Mobile: +44 7480 852 717 or http://www.aylanetworks.com/HOL-Registration. Limited spots available. Sign up now.
Cost: Free upon registration
Who: Solutions Engineers, Ayla Evangelists and Regional Account Directors from Ayla Networks will leading the event.
Key Audience: The Hands-on IoT Lab is aimed at development engineers through technical architects at manufacturing companies with products that are or could be connected to the IoT.
Extra Details: At each Hands-on IoT Lab session, appetizers and beverages are included. Participants will leave the lab with a binder of documentation.
Bonus: At each Hands-on IoT Lab session, there will be a drawing for one Apple Watch.
About Ayla Networks
Ayla Networks provides the industry’s first Agile IoT platform, accelerating development, support and ongoing enhancements of connected products for the Internet of Things. Ayla’s end-to-end platform runs across devices, cloud and apps to create secure connectivity, data analytics and feature-rich customer experiences. Delivered as a cloud platform-as-a-service (PaaS), Ayla’s Agile IoT platform provides the flexibility and modularity to enable rapid changes to practically any type of device, cloud or app environment. Ayla Networks was named a 2015 Cool Vendor in the Internet of Things by Gartner, Inc. Ayla’s investors include Cisco, the International Finance Corporation, SAIF Partners, Crosslink Capital, Voyager Capital, Linear Venture and SJF Ventures. For more information, visit www.aylanetworks.com.
Colleen Martell, +1 408-832-0147
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial9.12.2017 18:00 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the open-label, single-arm Phase II ACE-LY-004 clinical trial, which served as the basis for the recent US Food and Drug Administration (FDA) accelerated approval of Calquence (acalabrutinib). The findings were presented for the first time during an oral session at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA and demonstrate the safety profile and efficacy of acalabrutinib in the management of previously-treated mantle cell lymphoma (MCL). Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The results presented for the first time to the medical community highlight the potential of Calquence as a treatment for people with relapsed or refractory mantle cell l
Sustained Benefit in Patients with Relapsed/Refractory Mantle Cell Lymphoma Demonstrated by 3.5 Year Follow-up Data of Imbruvica®▼(ibrutinib)9.12.2017 17:19 | Pressemelding
Today, Janssen-Cilag International NV (“Janssen”) announced results of a pooled analysis of relapsed/refractory (r/r) mantle cell lymphoma (MCL) patients treated with Imbruvica® (ibrutinib). The extended follow-up data demonstrated that patients treated with ibrutinib earlier (at first relapse) experienced the best clinical outcomes, both in terms of efficacy and tolerability. These data (abstract #151) were presented in an oral presentation at the 59th Annual American Society of Hematology (ASH) Meeting and Exposition in Atlanta, GA.1,2 Ibrutinib, a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, is jointly developed and commercialised by Janssen Biotech, Inc. and Pharmacyclics LLC, an AbbVie company. “Data from this large clinical trial data set with extended follow-up support the early use of ibrutinib in patients with relapsed or refractory mantle cell lymphoma,” said Simo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom